Artificial Intelligence (AI)

Sudden stillbirth still poses as one of the key challenges in maternal and fetus care, especially in developing nations where sophisticated labor ward monitoring systems cannot be afforded. It becomes very challenging to detect a pregnancy at risk early due to the combination of several risk factors related to both mother and the fetus. This paper presents the design of a Human-in-the-Loop Explainable Artificial Intelligence (XA)I-based predictive labor ward model to help detect composite risks related to sudden stillbirth. For this, the research considers clinical records on 90 pregnant mothers and then utilizes machine learning (ML) models such as Logistic Regression, Random Forest, and XGBoost for predictions. XAI algorithms are utilized to enhance transparency, interpretability, and clinician understanding of predictive results. It is found that the highest prediction accuracy can be achieved by usinsg the XGBoost-XAI method, which is superior to traditional approaches. Hypertension in mother, fetal distress, placental inefficiency, gestational diabetes, and prolonged labor are some of the most significant predictors of sudden stillbirth. The Human-in-the-Loop concept makes it more reliable.

Biodegradable polymers present an environmentally safe alternative to reduce plastic waste by replacing traditional petroleum-based plastics. This review covered their classification, synthesis, properties, applications, and limitations, with examples of natural polymers, for example, starch and cellulose, and synthetic polymers like polylactic acid (PLA), polyhydroxyalkanoates (PHA), polybutylene succinate (PBS), and polycaprolactone (PCL). Different synthesis techniques, including bacterial fermentation, polymerization, and blending, were discussed for their advantages and disadvantages. These polymers have many uses in industry, including packaging, agriculture, biomedical applications, and textiles, but some limiting conditions exist, such as high processing costs, mechanical strength, and biological dependence for breakdown. To overcome these obstacles, a range of factors such as cheap feedstocks, genetic engineering, and improved processing, including green catalysts and nanocomposites, are worth investigating. It is also important to contextualize biodegradability in real-world cases that will shed light on the actual impact these polymers will have on the environment. If we continue this innovative research, amending policies, and work together as a sector, then biodegradable polymers will lead sustainable initiatives and drive us in the right direction towards a circular economy.

Nanoparticle drug delivery systems have evolved as a revolutionary approach to the treatment of cardiovascular diseases (CVDs). These systems present a highly hopeful alternative to traditional drugs, which often have limited bioavailability, systemic toxicity, poor solubility, and a dearth of targeted therapeutic effect. Liposomal, polymeric, metallic, and dendrimer-based nanoparticles are just a few examples of nanoscale carriers that can deliver drugs to injured tissues in a targeted fashion. This facilitates controlled and sustained drug release while at the same time reducing off-targeting effects. Nanotechnology can potentially enhance therapeutic responses significantly by aiding in the stabilization of medication, circulation time, and cellular internalization. This, in turn, will help to reduce unwanted effects and enhance patient care. The application of nanoparticles in tissue engineering is not only limited to the delivery of drugs but also plays a critical role in the regeneration of heart tissue and function as good contrast agents for imaging purposes, allowing for real-time monitoring of diseases. However, despite their enormous promise, their widespread clinical use is hampered by obstacles such as the toxicity of nanoparticles, the quick clearance of the immune system, intricacy of manufacture on a large scale, and onerous regulatory approval procedures. The effective integration of nanoparticle therapeutics with traditional cardiovascular treatment will depend upon the successful solution of these issues through the creation of biocompatible materials, effective surface modifications, and scalable manufacturing processes. Under the purview of this research, the latest advances in drug delivery through nanotechnology are explored, the mechanisms by which therapeutic action is enhanced are explored, and the potential future directions for implementing these advances into cardiovascular therapy protocols are explored.